Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database

Authors: Ze-Ning Huang, Qi-Yue Chen, Chao-Hui Zheng, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Jun Lu, Long-Long Cao, Mi Lin, Ru-Hong Tu, Ju-Li Lin, Hua-long Zheng, Chang-Ming Huang

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

The types of patients with gastric adenocarcinoma (GA) for whom postoperative radiotherapy can improve the disease-specific survival rate (DSS) remain controversial. This study aims to explore the ideal indications.

Methods

Patients in the Surveillance, Epidemiology, and End Results (SEER) database with T3–4Nx or TxN+ GA from January 1988 to December 2012 were included and divided into a postoperative chemoradiotherapy group (Group R) and a postoperative chemotherapy group (Group C). We established a nomogram to predict DSS and then divided entire patient cohort into low-risk and high-risk groups based on the DSS predicted by the nomogram.

Results

The Cox multiple regression analysis demonstrated that various risk factors affected DSS for Group R. Based on these risk factors, a nomogram for predicting DSS was established. The decision curve indicated that the best clinical effect could be obtained when the threshold probability was 0–58%. The patients were then divided into low-risk (< 69 points) and high-risk (≥ 69 points) groups according to the five-year DSS predicted. DSS was significantly better for Group R than for Group C for high-risk patients (P < 0.001) but was similar for low-risk patients (P = 0.732).

Conclusion

At present, the National Comprehensive Cancer Network (NCCN) guidelines may include an overly broad range of indications for postoperative radiotherapy for patients with GA. For intestinal GA patients with a postoperative pathologic stage of T1 N1 who are younger than 65 years, have had more than 15 lymph nodes dissected, and have received postoperative chemotherapy, postoperative radiotherapy should not be recommended.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.10 [Internet]. Lyon: International Agency for Research on Cancer; 2010. Available from: http:// globocan.iarc.fr.Accessed February 10, 2011 Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.10 [Internet]. Lyon: International Agency for Research on Cancer; 2010. Available from: http:// globocan.​iarc.​fr.Accessed February 10, 2011
2.
go back to reference Stewart BW, Kleihues P. World Cancer report. Lyon: IARC Press; 2003. Stewart BW, Kleihues P. World Cancer report. Lyon: IARC Press; 2003.
6.
go back to reference Solomon NL, Cheung MC, Byrne MM, et al. Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?[J]. Ann Surg Oncol. 2010;17(1):98–108.CrossRef Solomon NL, Cheung MC, Byrne MM, et al. Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?[J]. Ann Surg Oncol. 2010;17(1):98–108.CrossRef
7.
go back to reference Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol. 2010;11(5):439–49.CrossRef Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol. 2010;11(5):439–49.CrossRef
9.
go back to reference Valentini V, Cellini F. Combined treatments in gastric cancer: radiotherapy[J]. I supplementi di Tumori : official journal of Società italiana di cancerologia . [et al.]. 2003;2(5):S39–44. Valentini V, Cellini F. Combined treatments in gastric cancer: radiotherapy[J]. I supplementi di Tumori : official journal of Società italiana di cancerologia . [et al.]. 2003;2(5):S39–44.
10.
go back to reference Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.CrossRef Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.CrossRef
11.
go back to reference Fiorica F, Cartei F, Enea M, et al. The impact of radiotherapy on survival in respectable gastric carcinoma: a meta-analysis of literature data[J]. Cancer Treat Rev. 2007;33(8):729–40.CrossRef Fiorica F, Cartei F, Enea M, et al. The impact of radiotherapy on survival in respectable gastric carcinoma: a meta-analysis of literature data[J]. Cancer Treat Rev. 2007;33(8):729–40.CrossRef
12.
go back to reference Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophagesl junction[ J]. N Engl J Med. 2001;345(10):725–30.CrossRef Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophagesl junction[ J]. N Engl J Med. 2001;345(10):725–30.CrossRef
13.
go back to reference Ajani JA, D’Amico TA, Almhanna K, et al. Gastric Cancer, version 32016, NCCN clinical practice guidelines in oncology[J]. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(10):1286–312.CrossRef Ajani JA, D’Amico TA, Almhanna K, et al. Gastric Cancer, version 32016, NCCN clinical practice guidelines in oncology[J]. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(10):1286–312.CrossRef
14.
go back to reference Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.CrossRef Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.CrossRef
15.
go back to reference Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.CrossRef Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.CrossRef
16.
go back to reference Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with Capecitabine and cisplatin versus concurrent Chemoradiotherapy in gastric Cancer: final report of the adjuvant Chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.CrossRef Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with Capecitabine and cisplatin versus concurrent Chemoradiotherapy in gastric Cancer: final report of the adjuvant Chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.CrossRef
18.
go back to reference Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRef Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRef
19.
go back to reference Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routine technical report 61. Rochester: Mayo Foundation; 1997. Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routine technical report 61. Rochester: Mayo Foundation; 1997.
20.
go back to reference O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17:440–51.CrossRef O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17:440–51.CrossRef
21.
go back to reference Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011;29(15_suppl; abstr 4003):256s. Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011;29(15_suppl; abstr 4003):256s.
22.
go back to reference Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104(3):361–6.CrossRef Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104(3):361–6.CrossRef
23.
go back to reference Liang W, He J, Shen Y, et al. Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung Cancer: a population study of the US SEER database and a Chinese multi-institutional registry. J Clin Oncol. 2017 Apr 10;35(11):1162–70.CrossRef Liang W, He J, Shen Y, et al. Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung Cancer: a population study of the US SEER database and a Chinese multi-institutional registry. J Clin Oncol. 2017 Apr 10;35(11):1162–70.CrossRef
24.
go back to reference Hsu JT, Lin CJ, Sung CM, et al. Prognostic significance of the number of examined lymph nodes in node-negative GA. Eur J Surg Oncol. 2013;39:1287–93.CrossRef Hsu JT, Lin CJ, Sung CM, et al. Prognostic significance of the number of examined lymph nodes in node-negative GA. Eur J Surg Oncol. 2013;39:1287–93.CrossRef
25.
go back to reference Shiraishi N, Inomata M, Osawa N, et al. Early and late recurrence after gastrectomy for gastric carcinoma[J]. Cancer. 2000;89(2):255.CrossRef Shiraishi N, Inomata M, Osawa N, et al. Early and late recurrence after gastrectomy for gastric carcinoma[J]. Cancer. 2000;89(2):255.CrossRef
26.
go back to reference Lorenzon L, Mercantini P, Ferri M, et al. Lymph-node ratio classification strongly correlates with cancer survivals of patients who underwent r0 resection for gastric cancer with more than 15 nodes harvested[J]. European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes. 2014;53(1–4):1–10. https://doi.org/10.1159/000360937.CrossRefPubMed Lorenzon L, Mercantini P, Ferri M, et al. Lymph-node ratio classification strongly correlates with cancer survivals of patients who underwent r0 resection for gastric cancer with more than 15 nodes harvested[J]. European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes. 2014;53(1–4):1–10. https://​doi.​org/​10.​1159/​000360937.CrossRefPubMed
28.
go back to reference Vickers AJ, Elkin EB. Decision curve analysis:a novel method for evaluating prediction models. Med Decis Making. 2006;26:565–74.CrossRef Vickers AJ, Elkin EB. Decision curve analysis:a novel method for evaluating prediction models. Med Decis Making. 2006;26:565–74.CrossRef
31.
go back to reference Wynants L,Timmerman D,Verbakel J,et al. Clinical utility of risk models to refer patients with adnexal masses to specialized oncology care: multicenter external validation using decision curve analysis[J].Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, .DOI:https://doi.org/10.1158/1078-0432.CCR-16-3248 CrossRef Wynants L,Timmerman D,Verbakel J,et al. Clinical utility of risk models to refer patients with adnexal masses to specialized oncology care: multicenter external validation using decision curve analysis[J].Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, .DOI:https://​doi.​org/​10.​1158/​1078-0432.​CCR-16-3248 CrossRef
Metadata
Title
Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database
Authors
Ze-Ning Huang
Qi-Yue Chen
Chao-Hui Zheng
Ping Li
Jian-Wei Xie
Jia-Bin Wang
Jian-Xian Lin
Jun Lu
Long-Long Cao
Mi Lin
Ru-Hong Tu
Ju-Li Lin
Hua-long Zheng
Chang-Ming Huang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4957-6

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine